Apr 01 2021 Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder View
Mar 23 2021 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results View
Mar 18 2021 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021 View
Mar 11 2021 Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference View
Feb 23 2021 Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference View
Dec 07 2020 Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder View
Oct 27 2020 Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones View
Jun 23 2020 Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms View
